Osimertinib
泰瑞沙 (Tagrisso)
A third-generation targeted pill for lung cancers driven by EGFR mutations, including brain metastases.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL — reimbursed for eligible indications.
Regulatory status
NMPA approved; in NRDL (negotiated price)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
International comparison
US list ~USD 18,000+/month
What this meansReported information that has not yet been independently confirmed.
SourceNo independent source on file.
NotesReported comparison, not independently verified.
What it treats
EGFR-mutated NSCLC, first-line and after earlier EGFR drugs; post-surgery (adjuvant) use.
How it is accessed in China
- Hospitals nationwide
- DTP pharmacies
NRDL price applies to insured Chinese patients; foreign self-pay price to be confirmed per hospital.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Osimertinib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.